[Anti-angiogenic drugs].

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Angiogenesis or neovascularization, the formation of neo-vessels, is a physiological phenomenon endued in vasculature, but is involved in various pathological conditions including cancers and ocular diseases. Angiogenesis is required for tumor growth and metastasis, whereas angiogenesis is the major cause of blindness in the adult. Bevacizumab, a neutralizing anti-VEGF monoclonal antibody, is developed as the first anti-angiogenic drug in 2004. Thereafter, various drugs targeting VEGF-mediated signals have been developed to control tumor angiogenesis. Thus, anti-angiogenic drugs are now recognized in the clinic as a major step forward for the treatment of cancers and ocular diseases. This review focuses on the current status of anti-angiogenesis treatment.

Original languageEnglish
Pages (from-to)1825-1829
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume68
Issue number10
Publication statusPublished - 2010 Oct

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of '[Anti-angiogenic drugs].'. Together they form a unique fingerprint.

Cite this